Articles related to LUNG CANCER
Smoker’s Painless Skin Nodules Flag a Fatal Diagnosis
An 87-year-old white man presented to a hospital emergency surgical department with two round, grayish-brown nodules on his abdomen. He had no other complaints except feeling tired and dizzy for the last few months. He had a 120 pack-year smoking history but was not taking any medications and had not experienced a cough, chest pain, shortness of breath, or other breathing problems.
Cardiology April 27th 2022
Adebrelimab Improves PFS, OS in Extensive-Stage Small Cell Lung Cancer
Compared to chemotherapy alone, adebrelimab plus chemotherapy nearly doubled 2-year OS and more than tripled 1-year PFS in patients with extensive-stage SCLC, according to results presented earlier this month at the AACR Annual Meeting 2022. The phase 3 CAPSTONE-1 study evaluated adebrelimab in combination with carboplatin plus etoposide, as first-line treatment for ES-SCLC.
Oncology, Medical April 26th 2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients with Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
This retrospective cohort study included 2,833 patients with stage IB to IIIA NSCLC who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study from August 18, 2014, to April 1, 2019. Although 93% received surgical resection, just 53% had adequate lymph node dissection and 57% received any adjuvant chemotherapy. The authors suggest more effort at optimizing use of proven therapies in this patient population.
Oncology, Medical March 22nd 2022
Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial
This study evaluates the effect of including a patient-reported electronic symptom scoring system in terms of outcomes. Symptoms scored included pain, fatigue, disturbed sleep, shortness of breath, and coughing. The intervention group reported fewer symptom threshold events than the control group in hospital and 4 weeks post discharge.
Oncology, Medical March 22nd 2022
Lung Screening’s Benefits, Challenges
In March 2021, the US Preventive Services Task Force expanded the eligibility for lung cancer screening by setting the benchmark at a 20 pack-year smoking history for those ages 50 to 80 years who are current smokers or former smokers who have quit within the past 15 years. The new criteria will boost the number of eligible adults by 87% overall, according to a modeling analysis. It also could reduce lung cancer deaths by 13% versus 10% previously.
Internal Medicine March 15th 2022
Lung Cancer: Five-Year Survival Outcomes from the PACIFIC Trial
This update on the PACIFIC trial comparing durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer demonstrated robust and sustained OS and durable PFS benefit. The updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression. These results establish a new benchmark for standard of care in this setting.
Oncology, Medical February 23rd 2022